The BRCA1-delta11q splice variant, which lacks the majority of exon 11 of BRCA1 and consequently bypasses the inactivating germline mutations in this specific exon, promoted resistance to PARP inhibitors and cisplatin in breast cancers (Wang Y. et al., 2016). The gene discussed is BRCA1; the disease is breast carcinoma.